Wells Fargo
HCWB icon

Wells Fargo’s HCW Biologics HCWB Stock Holding History

Wells Fargo’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-167
Closed -$360 – 7423
2026
Q1 		$360 Hold
167
– – ﹤0.01% 6422
2025
Q4 		$971 Sell
167
-116
-41% -$1.97K ﹤0.01% 6285
2025
Q3 		$6.29K Hold
283
– – ﹤0.01% 6033
2025
Q2 		$6.74K Buy
+283
New +$12.4K ﹤0.01% 6030
2024
Q2 		– Sell
-1
Closed -$247 – 7127
2024
Q1 		$247 Hold
1
– – ﹤0.01% 6446
2023
Q4 		$169 Hold
1
– – ﹤0.01% 6645
2023
Q3 		$249 Buy
+1
New +$495 ﹤0.01% 6531
2023
Q2 		– Hold
0
– – – 6673
2023
Q1 		– Hold
0
– – – 6865
2022
Q4 		– Hold
0
– – – 6640
2022
Q3 		– Hold
0
– – – 6920
2022
Q2 		– Hold
0
– – – 7066
2022
Q1 		– Hold
0
– – – 7350
2021
Q4 		– Hold
0
– – – 7453
2021
Q3 		– Hold
0
– – – 7184

Other funds holding HCWB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Wells Fargo's HCWB Position: Q2 2026 in Review

Wells Fargo sold out of HCW Biologics (HCWB) in Q2 2026, closing a stake of 167 shares — an estimated $360 sold.

Wells Fargo first reported a position in HCWB in Q3 2023 and held it in 7 quarters. The position peaked at $6.74K in Q2 2025. 12 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

  • Wells Fargo reported no remaining HCW Biologics position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 167 HCW Biologics shares in Q2 2026, an estimated $360.
  • Wells Fargo first reported a position in HCW Biologics in Q3 2023 and held it in 7 quarters.
  • Wells Fargo's HCW Biologics position peaked at $6.74K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.